Oct 1, 2025, 08:40 AM by

Oct 1, 2025, 08:40 AM by

Oct 1, 2025, 01:01 AM by User Not Found

Bio-IT World | Bio-IT World is now accepting entries for the 2026 Innovative Practices Awards, a competition designed to recognize the most exciting partnerships and projects pushing the life sciences industry forward. The deadline for entry is March 2, 2026, and the $300 application fee will be waived for entrants who meet the early submission deadline of January 30, 2026.

Sep 30, 2025, 08:47 AM by

Sep 30, 2025, 08:47 AM by

Sep 30, 2025, 08:47 AM by

Pathologists readily embrace the shift to digital workflows.

Sep 30, 2025, 01:00 AM by User Not Found

Bio-IT World | Coming up with a medication that produces weight loss or prevents weight gain without any of the miserable side effects associated with top-selling drugs like Ozempic and Zepbound is the holy grail of every pharma company in the obesity space. About 70% of Americans are now considered overweight or obese, but relatively few of them are currently being treated with the otherwise popular weight-loss medications due in large part to side effects associated with the glucagon-like peptide-1 (GLP-1) pathway they activate in the gut and brain to achieve their effects.

Sep 29, 2025, 08:26 AM by

Sep 26, 2025, 01:01 AM by User Not Found

Bio-IT World | A new classification system for recurrent ovarian cancer was developed by scientists at Lausanne University Hospital and the Ludwig Institute for Cancer Research. The system combines genomic sequencing with immune profiling to stratify patients into four immunologic subgroups, laying the groundwork for personalized therapies that could extend survival.

Sep 25, 2025, 08:55 AM by

Delivering a menu of H&E, IHC, and special stains on the Concentriq platform

Sep 25, 2025, 08:55 AM by

Takara Bio Europe announces the launch of Cellartis® MSC EV Wonder.

Sep 25, 2025, 08:55 AM by

Sep 25, 2025, 08:55 AM by

PubHive launches Generative AI Usage Dashboard to give life sciences teams visibility, compliance, and cost control for responsible AI adoption.

Sep 25, 2025, 01:00 AM by User Not Found

Bio-IT World | National Institute of Standards and Technology (NIST) has collaborated with biotech company MilliporeSigma and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to create a “living” reference material; the Pistoia Alliance plans to establish a new initiative to advance the safe adoption of agentic AI; and more.

Sep 25, 2025, 01:00 AM by User Not Found

Bio-IT World | National Institute of Standards and Technology (NIST) has collaborated with biotech company MilliporeSigma and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to create a “living” reference material; the Pistoia Alliance plans to establish a new initiative to advance the safe adoption of agentic AI; and more.

Sep 24, 2025, 01:01 AM by User Not Found

Bio-IT World | Odyssey Therapeutics aims to transform the standard of care for patients suffering from autoimmune and inflammatory diseases; Dualitas will advance a portfolio of next-generation bispecific antibodies (BsAbs), including in allergic disease and autoimmune disease, and their discovery engine; and more.

Sep 22, 2025, 09:44 AM by

New kit enables rapid, accurate titre measurement across broad range of IgG subclasses and species on Amperia platform

Sep 22, 2025, 09:44 AM by

Lindus Health and Frieda Health Successfully Complete Clinical Trial Evaluating Novel Treatment for Menopause Symptoms

Sep 22, 2025, 09:44 AM by

Arkivum is delighted to announce a new partnership with PHARMASEAL, the provider of the Engility® Trial Management Platform, consisting of a Clinical Trial Management System (CTMS) and Electronic Trial Master File (eTMF).

Sep 22, 2025, 09:44 AM by

Hunan Huateng Pharmaceutical Co., Ltd. provides 1-Methyl-1H-Pyrazole-4-Carboxylic Acid (CAS 5952-92-1), a high-purity intermediate used in the synthesis of Aficamten (CK-274), an investigational cardiac myosin inhibitor currently in Phase 3 trials for hypertrophic cardiomyopathy.